Neurogene (NASDAQ:NGNE) Stock Rating Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Neurogene from “strong sell” to “sell,” while the broader analyst consensus remains “Buy” with an average price target of $79.57.
• Several firms maintained Buy ratings, though some trimmed price targets; Neurogene reported a quarterly loss of $1.05 per share, narrower than the estimated $1.36 loss.
• Institutional investors own 52.37% of the stock, with BlackRock among firms that recently established a sizable position.

Neurogene (NASDAQ:NGNE - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

Other analysts also recently issued reports about the company. Guggenheim increased their price objective on Neurogene from $69.00 to $81.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. began coverage on Neurogene in a research report on Thursday, October 8th. They set an "overweight" rating and a $60.00 target price on the stock. HC Wainwright decreased their price target on Neurogene from $65.00 to $60.00 and set a "buy" rating for the company in a report on Tuesday. Canaccord Genuity Group decreased their price target on Neurogene from $180.00 to $166.00 and set a "buy" rating for the company in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Neurogene in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $79.57.

Neurogene Stock Performance

NGNE opened at $23.93 on Friday. Neurogene has a fifty-two week low of $15.93 and a fifty-two week high of $43.66. The company's 50-day moving average is $28.21 and its 200 day moving average is $28.08.

Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.31. As a group, research analysts predict that Neurogene will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new stake in Neurogene in the 2nd quarter valued at about $904,000. BlackRock Inc. purchased a new position in shares of Neurogene in the 2nd quarter worth about $33,274,000. Renaissance Technologies LLC boosted its holdings in shares of Neurogene by 210.0% in the 1st quarter. Renaissance Technologies LLC now owns 43,400 shares of the company's stock worth $875,000 after buying an additional 29,400 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Neurogene in the 2nd quarter worth about $987,000. Finally, Deutsche Bank AG bought a new position in Neurogene during the second quarter valued at about $3,354,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Latest Neurogene News

These are some of the NGNE news items that stood out recently:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
• Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
• Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.

Neurogene Company Profile

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company's lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.